About Mobley Research Center
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Pfizer
3
Cell Genesys
2
AstraZeneca
1
Endo Pharmaceuticals
1
Medifocus, Inc.
1
Clinical Trials at Mobley Research Center
During the past decade, Mobley Research Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
2004-07-01
2008-10-01
Terminated
626
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
2005-07-01
2009-06-01
Terminated
408
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
2006-03-01
2008-10-01
Completed
565
Exploratory Study of Pagoclone in Men With Premature Ejaculation.
2006-07-01
2006-10-01
Completed
100
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
2008-03-17
2009-04-15
Completed
65
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
2010-01-22
2011-01-21
Terminated
205
Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)
2006-02-01
2018-08-01
Unknown status
250
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Mobley Research Center" #1 sponsor was "Pfizer" with 3 trials, followed by "Cell Genesys" with 2 trials
sponsored, "AstraZeneca" with 1 trials sponsored, "Endo Pharmaceuticals" with 1 trials sponsored and "Medifocus, Inc."
with 1 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
Clinical Trials Conditions at Mobley Research Center
According to Clinical.Site data, the most researched conditions in "Mobley Research Center" are
"Cystitis, Interstitial" (2 trials), "Prostate Cancer" (2 trials), "Benign Prostate Hyperplasia" (1 trials), "Diabetes Mellitus, Type 2" (1 trials) and "Neuralgia, Postherpetic" (1 trials). Many other conditions were trialed in "Mobley Research Center" in a lesser frequency.
Clinical Trials Intervention Types at Mobley Research Center
Most popular intervention types in "Mobley Research Center" are "Drug" (6 trials), "Biological" (3 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (4 trials), "Chemotherapy (Taxotere and prednisone)" (1 trials), "Chemotherapy (docetaxel and prednisone)" (1 trials), "Immunotherapy allogeneic GM-CSF secreting cellular vaccine" (1 trials) and "Immunotherapy with allogeneic prostate vaccine" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Mobley Research Center
The vast majority of trials in "Mobley Research Center" are
4 trials for "All" genders and 4 trials for "Male" genders.
Clinical Trials Status at Mobley Research Center
Currently, there are NaN active trials in "Mobley Research Center".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 4 completed trials in Mobley Research Center,
undefined suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in Mobley Research Center, 0 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".